Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

SNY

Sanofi ADR

Dec 13 • 04:00PM ET

46.80

Dollar change -0.19
Percentage change -0.40	%

Healthcare • Drug Manufacturers - General • France • NASD

Peers: NVS PFE MRK GSK BMY LLY AZN JNJ ABBV AMGN

| Held by: FVD GCOW PVAL PPH PID AVDE QQQJ APIE PLDR BUSA

Scroll to Statements

Index	-	P/E	25.80	EPS (ttm)	1.81	Insider Own	0.00%	Shs Outstand	2.61B	Perf Week	-3.43%
Market Cap	117.34B	Forward P/E	10.30	EPS next Y	4.54	Insider Trans	-	Shs Float	2.51B	Perf Month	-5.47%
Income	4.56B	PEG	3.16	EPS next Q	0.82	Inst Own	11.26%	Short Float	0.18%	Perf Quarter	-18.37%
Sales	47.68B	P/S	2.46	EPS this Y	-7.56%	Inst Trans	0.37%	Short Ratio	2.24	Perf Half Y	1.19%
Book/sh	31.14	P/B	1.50	EPS next Y	11.92%	ROA	3.31%	Short Interest	4.53M	Perf Year	-3.11%
Cash/sh	2.90	P/C	16.11	EPS next 5Y	8.18%	ROE	5.80%	52W Range	45.22 - 58.97	Perf YTD	-5.89%
Dividend Est.	2.02 (4.32%)	P/FCF	19.92	EPS past 5Y	2.68%	ROI	4.89%	52W High	-20.64%	Beta	0.55
Dividend TTM	2.04 (4.35%)	Quick Ratio	0.65	Sales past 5Y	2.80%	Gross Margin	61.47%	52W Low	3.49%	ATR (14)	0.69
Dividend Ex-Date	May 09, 2024	Current Ratio	1.00	EPS Y/Y TTM	-49.09%	Oper. Margin	21.26%	RSI (14)	27.18	Volatility	1.16% 1.30%
Employees	87994	Debt/Eq	0.33	Sales Y/Y TTM	5.18%	Profit Margin	9.56%	Recom	1.77	Target Price	60.05
Option/Short	Yes / Yes	LT Debt/Eq	0.20	EPS Q/Q	5.63%	Payout	63.38%	Rel Volume	1.71	Prev Close	46.99
Sales Surprise	3.35%	EPS Surprise	3.11%	Sales Q/Q	-13.36%	Earnings	Oct 25 BMO	Avg Volume	2.03M	Price	46.80
SMA20	-2.68%	SMA50	-8.51%	SMA200	-8.10%	Trades		Volume	3,463,004	Change	-0.40%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-26-24	Reiterated	Argus	Buy	$55 → $60
Jan-23-24	Initiated	Morgan Stanley	Equal-Weight	$55
Jan-16-24	Resumed	UBS	Buy
Dec-05-23	Downgrade	JP Morgan	Overweight → Neutral
Oct-30-23	Downgrade	Stifel	Buy → Hold
Sep-06-23	Upgrade	Berenberg	Hold → Buy
Jul-14-23	Initiated	HSBC Securities	Buy
Apr-28-23	Downgrade	Deutsche Bank	Hold → Sell
Mar-27-23	Upgrade	Barclays	Equal Weight → Overweight
Dec-13-22	Resumed	Morgan Stanley	Overweight
Aug-12-22	Upgrade	Deutsche Bank	Sell → Hold
Aug-09-22	Downgrade	UBS	Buy → Neutral
May-23-22	Initiated	SVB Leerink	Outperform
Sep-27-21	Upgrade	SVB Leerink	Mkt Perform → Outperform
Jan-15-21	Initiated	Deutsche Bank	Sell
Sep-29-20	Initiated	Berenberg	Hold
Mar-17-20	Upgrade	Barclays	Underweight → Equal Weight
Mar-11-20	Upgrade	Goldman	Neutral → Buy
Feb-11-20	Initiated	SVB Leerink	Mkt Perform
Jan-06-20	Upgrade	JP Morgan	Neutral → Overweight

Show Previous Ratings

Dec-13-24 09:59AM	Novavax Cut Its Outlook Despite Beating Third-Quarter Forecasts. Is It A Sell In December 2024? (Investor's Business Daily)
01:00AM	Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis (GlobeNewswire)
Dec-12-24 05:54PM	Gilead appoints Sanofi official Dietmar Berger as next chief medical officer (Reuters)
04:34AM	Sanofis combo vaccines gain FDA fast track designation (Pharmaceutical Technology)
Dec-11-24 01:00AM	Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US (GlobeNewswire)
10:33AM	Loading…
Dec-10-24 10:33AM	RSV prophylactic market to reach $6.2bn in 8MM by 2030 (Pharmaceutical Technology)
Dec-09-24 02:06PM	Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients (GlobeNewswire)
07:21AM	Sanofis Phase III trial of rilzabrutinib for thrombocytopenia meets endpoint (Clinical Trials Arena)
Dec-07-24 11:30AM	Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP (GlobeNewswire)
Dec-06-24 01:30AM	Press Release: Availability of the revised financial statements for Sanofi excluding Opella (GlobeNewswire)
Dec-03-24 01:05PM	Trump 2.0 could see a rise in biopharmaceutical M&A deals (Pharmaceutical Technology)
04:30AM	China welcomes new US$1 billion Sanofi project in Beijing (South China Morning Post)
12:41AM	Sanofi to Invest $1.05 Billion in New Insulin Manufacturing Base in China (The Wall Street Journal)
Dec-02-24 07:49AM	Analyst Report: Sanofi (Morningstar Research)
06:35AM	Sanofi announces its biggest China investment deal amid China-EU trade tensions (Reuters)
11:27AM	Loading…
Nov-30-24 11:27AM	Why Sanofi (SNY) Is One of the Best ADR Stocks to Invest in? (Insider Monkey)
Nov-29-24 01:00AM	Sanofis chief digital officer says remote work means employees lose the serendipity needed to innovate (Fortune)
Nov-27-24 05:45AM	Sanofi CEO Paul Hudson takes inspiration from Fight Club to get his team hooked on AI (Fortune)
Nov-26-24 04:03AM	Sanofi joins J&J, Eli Lilly in proposing 340B rebate model (Healthcare Dive)
Nov-25-24 08:41AM	Trumps presidency return: boom or bust for biopharmaceutical deal activity? (Pharmaceutical Technology)
Nov-22-24 12:32PM	Sanofi plans to change hospital drug-discount program (Reuters)
Nov-20-24 10:22AM	Heres What Drove Sanofis (SNY) Earnings (Insider Monkey)
08:11AM	Sanofi: Information concerning the total number of voting rights and shares - October 2024 (GlobeNewswire)
Nov-18-24 12:46AM	Analyst Report: Sanofi (Morningstar Research)
Nov-15-24 04:18PM	How analysts are reacting to RFK Jr. as Trump's HHS pick (Yahoo Finance Video)
12:40PM	FDA reviews Sanofi and Regenerons Dupixent label expansion for urticaria (Pharmaceutical Technology)
12:15PM	Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk (The Wall Street Journal)
11:15AM	Trumps RFK Jr. Pick Weighs on Vaccine Makers (The Wall Street Journal)
09:43AM	Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of. (Yahoo Finance)
07:00AM	FDA to review Sanofi, Regeneron's Dupixent sBLA for CSU (Pharmaceutical Business Review)
06:45AM	Loading…
06:45AM	RFK Jr. News Hits Global Pharma Stocks (The Wall Street Journal)
05:19AM	European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department (The Wall Street Journal)
04:36AM	EMAs CHMP recommends Sanofis Sarclisa approval for multiple myeloma (Pharmaceutical Technology)
03:15AM	Drugmaker stocks slide as Trump picks vaccine sceptic RFK Jr for US health job (Reuters)
01:00AM	Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria (GlobeNewswire)
12:59AM	Dupixent (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU) (GlobeNewswire)
Nov-14-24 11:42AM	Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma (GlobeNewswire)
Nov-13-24 11:06AM	Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease (Benzinga)
02:08AM	Novavax Inc (NVAX) Q3 2024 Earnings Call Highlights: Strategic Partnerships and Financial ... (GuruFocus.com)
Nov-12-24 02:43PM	Novavax: Stock plunges after quarterly earnings, but sees hope in licensing deals (Yahoo Finance)
02:43PM	Novavax stock plunges after quarterly earnings, but company sees hope in licensing deals (Yahoo Finance)
08:05AM	Novavax cuts 2024 revenue forecast again on lower COVID vaccine sales (Reuters)
Nov-11-24 06:00AM	Recordati SpA (RICFY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ... (GuruFocus.com)
Nov-08-24 01:02PM	Is Novavax Stock A Sell After An Unexpected Side Effect Torpedoed Its Testing Plans? (Investor's Business Daily)
09:38AM	Analyst Report: Sanofi (Morningstar Research)
Nov-07-24 05:42AM	Advent Mulls 5 Billion Sale of Generic Drugmaker Zentiva (Bloomberg)
04:28AM	EMA approves Sanofi/Regenerons Dupixent for young EoE patients (Pharmaceutical Technology)
Nov-06-24 01:00AM	Press Release: Dupixent approved in the EU as the first and only medicine for young children with eosinophilic esophagitis (GlobeNewswire)
01:00AM	Dupixent (dupilumab) Approved in the European Union as the First and Only Medicine for Young Children with Eosinophilic Esophagitis (GlobeNewswire)
Nov-01-24 05:01PM	Vir Biotechnology Inc (VIR) Q3 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com)
03:07AM	Kymera Therapeutics Inc (KYMR) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
Oct-30-24 12:14PM	Q3 2024 BioMarin Pharmaceutical Inc Earnings Call (Thomson Reuters StreetEvents)
Oct-28-24 05:54PM	Beyfortus® immunization to protect infants from RSV has begun (PR Newswire)
Oct-26-24 03:04AM	Sanofi SA (SNY) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Advances (GuruFocus.com)
Oct-25-24 06:55PM	Analyst Report: Sanofi (Morningstar Research)
05:23PM	Why Sanofi Stock Flew Higher on Friday (Motley Fool)
04:24PM	Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat (Investor's Business Daily)
03:00PM	Sanofi (SNY) Q3 2024 Earnings Call Transcript (Motley Fool)
01:57PM	Eli Lilly's Newly FDA-Approved Eczema Drug Improves Skin And Itch In Patients Previously Treated With Sanofi/Regeneron's Dupixent (Benzinga)
12:21PM	Sanofi Shocks the Market: Massive Q3 Surge, Game-Changing Moves, and Bold Divestment Plans (GuruFocus.com)
11:22AM	Sanofi-backed Agomab raises $89m to advance fibrotic disease treatments (Pharmaceutical Technology)
07:56AM	Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off (CNBC TV)
07:50AM	Sanofi earnings boosted by Beyfortus, earlier vaccine sales (BioPharma Dive)
07:18AM	Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast (Benzinga)
05:44AM	Sanofi Earnings Get Boost From Early Vaccine Sales (The Wall Street Journal)
05:02AM	Sanofi: Q3 Earnings Snapshot (Associated Press Finance)
03:32AM	Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales (Investing.com)
03:06AM	Sanofi Profit Lifted by Early Vaccine Sales, Dupixent Growth (Bloomberg)
02:45AM	Sanofi Profit, Sales Beat Estimates (The Wall Street Journal)
01:32AM	Sanofi profit growth beats market view on early start of vaccine sales (Reuters)
01:30AM	Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance (GlobeNewswire)
Oct-24-24 08:00AM	Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI (GlobeNewswire)
08:00AM	Dupixent (dupilumab) Late-Breaking Positive Phase 3 Data in Chronic Spontaneous Urticaria to Be Presented at ACAAI (GlobeNewswire)
07:59AM	How Sanofi Was Caught in The Middle of a 16 Billion Public Brawl (Bloomberg)
Oct-23-24 07:57PM	Analyst Report: Sanofi (Morningstar Research)
Oct-21-24 05:02PM	Sanofi Deal Jitters Imperil Stocks Big Rebound (Barrons.com)
11:02AM	Sanofis $17bn sale of Opella to US investors advances following government deal (Pharmaceutical Technology)
09:08AM	Sanofi Engages In Exclusive Talks With US Private Equity CD&R For Its Consumer Health Business (Benzinga)
08:23AM	Sanofi moves ahead with CD&R deal for stake in consumer business (BioPharma Dive)
04:52AM	Stocks to Watch Monday: Boeing, Kenvue and Walmart (The Wall Street Journal)
04:36AM	CD&R Nears Sanofi OTC Deal After Signing With Government (Bloomberg)
04:21AM	Sanofi Enters Exclusive Talks With CD&R Over Consumer Business Stake Sale (The Wall Street Journal)
04:02AM	Sanofi and CD&R enter exclusive talks for Opella sale (Investing.com)
01:32AM	Sanofi in exclusive talks with CD&R over sale of $17 billion Opella (Reuters)
01:30AM	Press Release: Sanofi and CD&R partner to fuel Opella's ambitions in consumer healthcare (GlobeNewswire)
Oct-20-24 02:50PM	Sanofi reaches deal on terms of sale of consumer health arm, say French government sources (Reuters)
Oct-18-24 01:34PM	Sanofi Set to Sign Consumer Health Deal With CD&R This Weekend (Bloomberg)
07:02AM	Sanofi and Orano Med link for radioligand therapy development (Pharmaceutical Technology)
Oct-17-24 02:28PM	PAI Partners to Raise Offer for Sanofis Consumer Unit (Bloomberg)
08:17AM	Goldman, Citi Among 22 Banks on CD&Rs Buyout of Sanofi Unit (Bloomberg)
07:20AM	Sanofi, expanding in radiopharma, strikes a joint venture deal (BioPharma Dive)
07:11AM	Exscientia advances two additional discovery programs with Sanofi (TipRanks)
01:30AM	Press Release: Sanofi and Orano join forces to develop next-generation radioligand medicines (GlobeNewswire)
Oct-16-24 12:26PM	FLUBLOK (Influenza Vaccine) US label updated with one of Sanofi's largest flu vaccine safety studies in pregnant individuals (PR Newswire)
12:04PM	Sanofi in Talks With French Government to Address Concerns on Opella Deal (The Wall Street Journal)
06:00AM	Sanofi commits $18 million to Howard University College of Medicine, Meharry Medical College, and Morehouse School of Medicine to increase diversity in clinical studies (PR Newswire)
Oct-15-24 04:05PM	Sanofi: Information concerning the total number of voting rights and shares - September 2024 (GlobeNewswire)
10:09AM	Digital twins: A new path to personalised medicine (Verdict)
Oct-14-24 02:35PM	CD&R Plans Measures to Ease French Worries on Sanofi Deal (Bloomberg)
09:40AM	Should Value Investors Buy Sanofi (SNY) Stock? (Zacks)

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

SNY

Sanofi ADR

Upgrade your FINVIZ experience